BTIG Research Increases Guardant Health (NASDAQ:GH) Price Target to $145.00

Guardant Health (NASDAQ:GH) had its price target hoisted by investment analysts at BTIG Research from $140.00 to $145.00 in a research note issued on Friday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 40.64% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on GH. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 7th. Robert W. Baird began coverage on shares of Guardant Health in a research report on Tuesday. They set an “outperform” rating and a $120.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, January 22nd. Barclays restated an “overweight” rating and set a $130.00 target price on shares of Guardant Health in a research note on Friday. Finally, Wells Fargo & Company lifted their price target on Guardant Health from $93.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Twenty-one analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $117.43.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $103.10 on Friday. The business’s 50 day simple moving average is $106.69 and its 200 day simple moving average is $86.22. Guardant Health has a 1 year low of $34.88 and a 1 year high of $120.74. The company has a market capitalization of $12.99 billion, a P/E ratio of -31.15 and a beta of 1.63.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. The business’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same period last year, the firm posted ($0.62) EPS. On average, sell-side analysts anticipate that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Activity

In related news, CEO Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the sale, the chief executive officer owned 168,223 shares of the company’s stock, valued at $17,671,826.15. This trade represents a 37.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 90,565 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the transaction, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 434,511 shares of company stock valued at $45,580,887. 6.10% of the stock is currently owned by insiders.

Institutional Trading of Guardant Health

Hedge funds have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in shares of Guardant Health in the third quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Norges Bank acquired a new position in Guardant Health in the 4th quarter valued at approximately $128,499,000. Franklin Resources Inc. raised its stake in shares of Guardant Health by 78.2% during the second quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after acquiring an additional 1,018,144 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Guardant Health by 27.3% during the second quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after purchasing an additional 763,834 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health News Roundup

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.